The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
News|Articles|April 1, 2025
FDA updates in urology: March 2025
Author(s)Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from March 2025.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! This month, key developments include the initiation of a pivotal trial in stress urinary incontinence (SUI), an expanded indication for radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC), and the approval of a new treatment regimen in muscle-invasive bladder cancer (MIBC).
Related to this article
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
Advertisement
Advertisement